Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to Mark to make it happen.
Free
Posted in: Autologous, CAR-T, CD19 May 20 | 2022Yescarta in 2L LBCL and Tecartus in R/R ALL Absent from May’s CHMP HighlightsAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 May 16 | 2022Gracell Q1 2022 Earnings CallAccess Free BlastFree
Posted in: CAR-T, CD19 May 16 | 2022Could Yescarta in 2L LBCL Receive a CHMP Positive Opinion This Week?Access Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19, TCR May 13 | 2022TCR2 Tx, Poseida, 2seventy bio, and Cellectis Q1 2022 EarningsAccess Free Blast
Free
Posted in: Allogeneic, Autologous, TCR May 09 | 2022Afami-cel’s BLA Filing Remains On Track for Q4 2022; ADP-A2M4N7X19’s IND Submission Planned by YE 2022; Precision's Clinical Updates Expected in June 2022; Adaptimmune and Precision Q1 2022 Earnings SummariesAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19, CD22 May 06 | 2022Autolus to Evaluate MRD Status in Obe-cel’s FELIX Trial; First Patient Dosed in AUTO8’s MCARTY Study; Autolus Q1 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, CAR-T, CD19 May 05 | 2022Allogene Plans to Evaluate ALLO-501A in 2L DLBCL; No Updates for Allogene’s BCMA Programs; ALLO-316’s Initial Data Likely Delayed to 2023; CF1 to Produce ~20,000 Doses Annually; Allogene Q1 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 May 02 | 2022Breyanzi’s Sales Increase While Abecma’s Remain Flat; BMS Prepares for an Increase in Cell Therapy Demand; No Clinical Milestone Updates for Breyanzi or Abecma; BMS’s Q1 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Apr 29 | 2022Gilead’s Cell Therapy Sales Continue to Grow; Gilead’s New Manufacturing Facility Could Accelerate Yescarta’s Launch in 2L LBCL; Gilead’s Q1 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Apr 29 | 2022Gilead’s Oncology Deep Dive 2022: Celltelligence Analysis - Part 2Access Free Blast
Free
Posted in: Autologous, TCR Apr 27 | 2022No Updates for GSK's Cell Therapy Assets; New GSK Expected to Launch in July 2022; GSK’s Q1 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD123, CD19 Apr 27 | 2022Kymriah's Sales Decline; PHE885 Pivotal Study Initiated; YTB323’s Anticipated Submission Delayed to 2025; Novartis’s Q1 2022 Earnings Call SummaryAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 Apr 25 | 2022Autolus’s Obe-cel Receives FDA RMAT Designation; JNJ / Legend Update Carvykti’s HCP WebsiteAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Apr 22 | 2022CHMP Adopts Positive Opinion for Yescarta in ≥4L FL; Yescarta in 2L DLBCL Absent from April’s CHMP MeetingAccess Free Blast
Free
Posted in: Autologous, BCMA Apr 21 | 2022Legend Achieves Another Milestone Payment from Janssen for CarvyktiAccess Free Blast
Free
Posted in: BCMA, CAR-T Apr 20 | 2022Is Carvykti’s Launch Constrained by JNJ’s Manufacturing Capacity? JNJ Q1 2022 Earnings Call SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Apr 19 | 2022Could Yescarta in r/r FL Receive a CHMP Positive Opinion This Week?Access Free BlastFree
Posted in: Allogeneic, Autologous, CD19, Other Apr 15 | 2022Gilead’s Oncology Deep Dive 2022: Celltelligence Analysis - Part 1Access Free Blast
Free
Posted in: Autologous, CAR-T, TCR Apr 14 | 2022Fate’s Novel FT573 Pan-Tumor Targeting Asset and Tri-Modal CAR-TCR Platform; Shoreline’s iPSC-derived Screening Platform; BMS’s Abecma to be Reimbursed in Japan on April 20; AACR 2022 Final AnalysisAccess Free BlastFree
Posted in: Allogeneic, Autologous, CAR-T Apr 13 | 2022Different Strategies for Enhancing CAR-Ts to Treat Solid Tumors; Preclinical Results from Allogene’s ALLO-316; TCR2 Tx’s Allogeneic TRuC-T Platform; AACR 2022 Analysis 4Access Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Mark.